Head, Targeted Protein Degradation & Proximity Therapeutics

Initial Therapeutics, Inc.; Thousand Oaks (CA); On-site; USD 160,000 - 220,000; Full time

Benefits offered by this job

Comprehensive employee benefits package

Stock-based long-term incentives

Flexible work models

Job summary

Initial Therapeutics, Inc. is seeking a Director for its Targeted Protein Degradation team to lead scientific strategy and innovation within the Induced Proximity Platform. This role requires a recognized leader in targeted protein degradation with experience in managing teams and translating scientific advancements into practical drug discoveries.

The successful candidate will oversee a multidisciplinary team, driving developments and establishing partnerships to expand capabilities in drug discovery, ensuring the application of cutting-edge research to address high-value therapeutic targets.

Qualifications

• Doctorate or equivalent experience in relevant scientific discipline.
• Experience managing teams and resources.
• Track record in drug discovery or related fields.

Responsibilities

• Define the strategic vision for targeted protein degradation.
• Build and mentor a team of scientists in relevant fields.
• Drive innovation in induced proximity therapeutics.

Skills

Leadership

Targeted protein degradation expertise

Strategic planning

Collaboration

Chemical biology

Education

Doctorate degree

Master’s degree

Bachelor’s degree

Job description

Initial Therapeutics, Inc. is seeking a Director for its Targeted Protein Degradation team to lead scientific strategy and innovation within the Induced Proximity Platform. This role requires a recognized leader in targeted protein degradation with experience in managing teams and translating scientific advancements into practical drug discoveries.

The successful candidate will oversee a multidisciplinary team, driving developments and establishing partnerships to expand capabilities in drug discovery, ensuring the application of cutting-edge research to address high-value therapeutic targets.